Excitatory Amino Acids
11%
off

Excitatory Amino Acids : Clinical Results with Antagonists

Edited by 

Free delivery worldwide

Available. Dispatched from the UK in 1 business day
When will my order arrive?

Description

Glutamate is the major excitatory neurotransmitter in the brain and dysfunction of glutamate transmission is the likely cause of a variety of diseases including neurodegeneration following cerebral ischemia, Huntington's chorea, amyotrophic lateral sclerosis, epilepsy, spasticity, emesis, chronic pain, and schizophrenia. Excitatory amino acid receptor agonists and antagonists are therefore of major interest as potential drugs for central nervous system disorders. Excitatory Amino Acids is the first book entirely dedicated to the results of human testing of modulators of excitatory amino acid neurotransmitters.
show more

Product details

  • Hardback | 156 pages
  • 194.3 x 261.6 x 14mm | 522.53g
  • Academic Press Inc
  • San Diego, United States
  • English
  • 0125468202
  • 9780125468206

Table of contents

M. Schmutz, A. Arthur, H. Faleck, G. Karlsson, A. Kotake, L. Landwicki, L. LaRue, S. Markabi, D. Murphy, M. Powell, and D. Sauer, Selfotel.
P. Herrling et al., D-CPPene (SDZ EAA-494) A Competitive NMDA Antagonist: Pharmacology and Results in Humans.
J.D. Kristensen, Intrathecal Administration of a Competitive NMDA Receptor Antagonist for Pain Treatment.
A.G. Knapp, L.I. Matthews, and E.R. Gamzu, Clinical Experience with the NMDA Ion-Channel Blocker, Aptiganel Hydrochloride (CEROSTAT).
M.-L. Maccecchini, Development of ACPC: A Partial Agonist of the Glycine Site on the NMDA Receptor.
Carter et al., Ifenprodil and Eliprodil: Neuroprotective NMDA Receptor Antagonists and Calcium Channel Blockers.
D. Lodge and D.D. Schoepp, 3S, 8aR-6-[2-(1(2)H-tetrazole-5-y)ethyl] Decahydroisoquinoline-3-carboxylic Acid (LY293558) and Its Racemate (LY215490): A Selective and Competitive AMPA/Kainate Receptor Agonist.
L. Nordholm, M. Sheardown, and T. Honore, The NBQX Story.
E. Louvel, Riluzole in Amytrophic Lateral Sclerosis.
G.C. Plamer and J.B. Hutchinson, Preclinical and Clinical Aspects of Remacemide Hydrochloride.
show more

Review quote

"This book is intended for research neuroscientists but can be effectively utilized by clinicians and students because of its clarity of style and excellent illustrations... Many excellent diagrams and charts are scattered throughout this volume. They make for easy conceptualization of the results of preclinical as well as phase one and two clinical trials... This book provides a much needed report on these exciting neuroprotective agents, several of which will be released by the FDA in the near future." --Thomas H. Jobe, MD, University of Illinois at Chicago College of Medicine for DOODY'S PUBLISHING REVIEWS
show more

About Paul L. Herrling

Paul L. Herrling is currently Head of Corporate Research at Sandoz Pharmacies in Basel, Switzerland.
show more